Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,762 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Major Depressive Disorder
Interventions: Aripiprazole+ ADT, Placebo+ ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 34
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 29 more

Conditions: Major Depressive Disorder
Interventions: eicosapentaenoic acid, docosahexaenoic acid, Placebo; Dietary Supplement · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Depression
Interventions: Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.; Drug · Device
Lead sponsor: Marta Peciña, MD PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder, Depression
Interventions: Fluoxetine, Psychotherapy; Drug · Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 12 Years to 17 Years
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 12
States / cities: Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 8 more

Conditions: Major Depressive Disorder, Cardiovascular Diseases, Inflammation, Blood Pressure, Heart Rate Variability
Interventions: Single-session emotion regulation training; Behavioral
Lead sponsor: University of Southern Mississippi; Other
Eligibility: 18 Years to 29 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Seasonal Affective Disorder, Mood Disorders, Depression
Interventions: bright light box, dawn simulator, high-output negative ion generator, low-output negative ion generator, dawn light pulse; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Huntsville, Alabama • Pico Rivera, California • Farmington, Connecticut + 21 more

Conditions: Healthy
Interventions: DSP-1053, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: MDD
Interventions: TMS treatment; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Bone Diseases, Metabolic, Depression, Involutional, Osteoporosis
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Ketamine Hydrochloride, Midazolam injection; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depression, Opioid-use Disorder, Opioid Abuse
Interventions: Ketamine Hydrochloride, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
Interventions: Wellth - Financial Incentives; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Major Depressive Disorder
Interventions: FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs); Drug
Lead sponsor: Adams Clinical; Network
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Cannabis Use Disorder, Major Depression, Anhedonia, Transcranial Alternating Current Stimulation
Interventions: Transcranial Alternating Current Stimulation Sham, Transcranial Alternating Current Delta Stimulation., Transcranial Alternating Current Theta Stimulation; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Tallahassee, Florida

Conditions: Major Depression
Interventions: High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires; Device · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Major Depressive Disorder, Anhedonia
Interventions: Psilocybin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Suicidal Ideation, Major Depressive Disorder
Interventions: MagVenture TMS Therapy System w/Theta Burst Stimulation, Sham MagVenture TMS Therapy System w/Theta Burst Stimulation; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Depression, Depressive Disorder, Depressive Disorder, Major
Interventions: Buprenorphine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, Major Depressive Disorder
Interventions: Nitrous Oxide, Placebo; Drug
Lead sponsor: Bayside Health; Government
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depression, Dysthymia, Depression NOS
Interventions: escitalopram + bupropion; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: duloxetine, Placebo, fluoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 24
States / cities: Costa Mesa, California • Irvine, California • Palo Alto, California + 21 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more

Search by objective public record fields.

A Study of Aripiprazole in Patients With Major Depressive Disorder

Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Treatment for Adolescents With Depression Study (TADS)

Emotion Regulation Training to Reduce Cardiovascular Disease Risk Among Depressed Young Adults in Southern Mississippi

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder

Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression

Developing New Clinical Management Strategies

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

Ketamine for the Treatment of Opioid Use Disorder and Depression

Financial Incentives to Improve Medication Adherence

Tracking Response to Antidepressants in Advance of Investigational Trials

Neuromodulation of Motivation and Reward Oscillations

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

PET Synaptogenesis After Psilocybin In DEpression Recovery

Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation

Buprenorphine for Treatment Resistant Depression

Nitrous Oxide for the Treatment of Major Depressive Disorder

Are Two Antidepressants a Good Initial Treatment for Depression?

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment